239 related articles for article (PubMed ID: 35159934)
21. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.
Della Starza I; De Novi LA; Elia L; Bellomarino V; Beldinanzi M; Soscia R; Cardinali D; Chiaretti S; Guarini A; Foà R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672325
[TBL] [Abstract][Full Text] [Related]
22. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
Selim AG; Moore AS
J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.
Aguirre-Ruiz P; Ariceta B; Viguria MC; Zudaire MT; Blasco-Iturri Z; Arnedo P; Aguilera-Diaz A; Jauregui A; Mañú A; Prosper F; Mateos MC; Fernández-Mercado M; Larráyoz MJ; Redondo M; Calasanz MJ; Vázquez I; Bandrés E
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33255857
[TBL] [Abstract][Full Text] [Related]
24. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
25. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.
Della Starza I; Nunes V; Lovisa F; Silvestri D; Cavalli M; Garofalo A; Campeggio M; De Novi LA; Soscia R; Oggioni C; Mussolin L; Biondi A; Guarini A; Valsecchi MG; Conter V; Biffi A; Basso G; Foà R; Cazzaniga G
Hemasphere; 2021 Mar; 5(3):e543. PubMed ID: 33655199
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
27. Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Yoest JM; Shirai CL; Duncavage EJ
Front Cell Dev Biol; 2020; 8():249. PubMed ID: 32457898
[TBL] [Abstract][Full Text] [Related]
28. Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.
Roloff GW; Lai C; Hourigan CS; Dillon LW
J Clin Med; 2017 Sep; 6(9):. PubMed ID: 28925935
[TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
30. Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
Pichon M; Gaymard A; Josset L; Valette M; Millat G; Lina B; Escuret V
Antiviral Res; 2017 Sep; 145():160-167. PubMed ID: 28780426
[TBL] [Abstract][Full Text] [Related]
31. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
32. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
Leisch M; Jansko B; Zaborsky N; Greil R; Pleyer L
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30795628
[TBL] [Abstract][Full Text] [Related]
33. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
Tomlinson B; Lazarus HM
Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
[TBL] [Abstract][Full Text] [Related]
34. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
Thol F; Kölking B; Damm F; Reinhardt K; Klusmann JH; Reinhardt D; von Neuhoff N; Brugman MH; Schlegelberger B; Suerbaum S; Krauter J; Ganser A; Heuser M
Genes Chromosomes Cancer; 2012 Jul; 51(7):689-95. PubMed ID: 22454318
[TBL] [Abstract][Full Text] [Related]
36. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
37. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract][Full Text] [Related]
39. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
40. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
